Microbix Biosystems Inc.

Equities

MBX

CA59501P1045

Biotechnology & Medical Research

Market Closed - Toronto S.E. 03:59:51 2024-04-19 pm EDT 5-day change 1st Jan Change
0.34 CAD -4.23% Intraday chart for Microbix Biosystems Inc. -4.23% -12.82%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Microbix Biosystems Inc. - Shareholder/Analyst Call
Microbix Says Clot-Buster Drug Project Advancing MT
Microbix Brief: Says Clot-Buster Drug Project Advancing MT
Microbix?S Clot-Buster Drug Project Advances CI
Microbix Unveiling Test Controls for Head and Neck Cancer MT
Microbix Brief: Unveiling Test Controls for Head and Neck Cancer MT
Microbix Biosystems Inc. Unveils Test Controls for Head and Neck Cancer CI
Microbix Higher After Reporting Record Results for Q1 Fiscal 2024 MT
Transcript : Microbix Biosystems Inc., Q1 2024 Earnings Call, Feb 14, 2024
Earnings Flash (MBX) MICROBIX BIOSYSTEMS Posts Q1 Revenue $8.4M MT
Tranche Update on Microbix Biosystems Inc.'s Equity Buyback Plan announced on December 6, 2023. CI
Microbix Biosystems Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023 CI
North American Morning Briefing :Stock Futures -2- DJ
Microbix Unveiling Test Control for Gastric Ulcer Disease Pathogen MT
Microbix Brief: Unveiling Test Control for Gastric Ulcer Disease Pathogen MT
Microbix Unveils Test Control for Gastric Ulcer Disease Pathogen CI
Microbix Systems Provides Update on QAP Sales MT
Microbix Brief: Says Achieved Further QAPs Sales Record; Includes Over C$1 Million in One Shipment to a Leading Lab Accreditation Agency MT
Transcript : Microbix Biosystems Inc., Q4 2023 Earnings Call, Jan 03, 2024
Microbix Reports Q4 Income of $2 Million MT
Microbix Brief: Q4 Net Comprehensive Income per share 0.014 Vs (0.009) a Year Ago MT
Microbix Brief: Q4 revenue was $4,264,229, relatively flat from Q4 2022 revenues MT
Microbix Biosystems Inc. Provides Earnings Guidance for the Full-Year Fiscal 2024 CI
North American Morning Briefing : Stock Futures Bounce Back After Worst One-Day Slide in Three Months DJ
Microbix Biosystems Inc. Reports Earnings Results for the Full Year Ended September 30, 2023 CI
Chart Microbix Biosystems Inc.
More charts
Microbix Biosystems Inc. is a Canada-based life science company, which develops and commercializes biological and technological solutions for human health and wellbeing. The Company manufactures a wide range of critical biological materials for the global diagnostics industry, mainly antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. It operates through two segments: the development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and the development and commercialization of products or technologies such as Kinlytic. Its Kinlyti urokinase is a biologic thrombolytic drug used to treat blood clots.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.34 CAD
Average target price
0.8 CAD
Spread / Average Target
+135.29%
Consensus
  1. Stock Market
  2. Equities
  3. MBX Stock
  4. News Microbix Biosystems Inc.
  5. Microbix Biosystems Presenting Test-Workflow Validation Results at European Meeting on Molecular Diagnostics